Pemphigus, Herpetiformis


Article Author:
Mehdi Karray


Article Editor:
Talel Badri


Editors In Chief:
Sisira Reddy
Joseph Nahas


Managing Editors:
Orawan Chaigasame
Carrie Smith
Abdul Waheed
Frank Smeeks
Kristina Soman-Faulkner
Benjamin Eovaldi
Radia Jamil
Sobhan Daneshfar
Saad Nazir
William Gossman
Pritesh Sheth
Hassam Zulfiqar
Navid Mahabadi
Steve Bhimji
John Shell
Matthew Varacallo
Ahmad Malik
Mark Pellegrini
James Hughes
Beata Beatty
Hajira Basit
Phillip Hynes


Updated:
6/4/2019 5:22:03 PM

Introduction

Pemphigus herpetiformis is a rare subtype of intraepidermal autoimmune bullous diseases that associate the clinical characteristics of dermatitis herpetiformis and the immunologic features of pemphigus. Although Jablonska and others proposed the name of this entity in 1975, similar clinical presentations were reported earlier and named dermatitis herpetiformis with acantholysis, mixed bullous disease, and pemphigus controlled by sulfapyridine.[1][2][3][4]

Etiology

Pemphigus herpetiformis appears to be an IgG-mediated autoantibody that mainly targets the desmoglein proteins of the epidermis. The mechanism by which autoantibodies produce characteristic skin lesions in pemphigus herpetiformis is still debated. Some cases of drug-induced pemphigus herpetiformis have otherwise been reported.[5][6][7][8]

Epidemiology

Pemphigus herpetiformis accounts for 6% to 7.3% among patients with pemphigus. Since the first description in 1975 by Jablonska and others, approximatively 100 cases have been reported in the literature. It equally affects men and women. The age of onset ranges from 5 to 92 years. Only four pediatric patients have been reported. Pemphigus herpetiformis does not appear to have a specific ethnic predominance since it has been reported from different continents including America, Europe, Asia, and Africa.

Pathophysiology

Target antigens for pemphigus herpetiformis are usually Desmoglein 1 (Dsg1) and less commonly Desmoglein 3 (Dsg3). Recently, several cases of pemphigus herpetiformis without anti-Dsg1 or anti-Dsg3 autoantibodies have been reported, and some patients show reactivity against other antigens such as desmocollin (Dsc). In contrast to pemphigus vulgaris and pemphigus foliaceous, pemphigus herpetiformis is characterized by an intense inflammation that may not be associated with acantholysis. In fact, pemphigus herpetiformis autoantibodies may recognize functionally less important epitopes of Dsg1 or Dsg3, and therefore, do not induce acantholysis. A recent study supports this hypothesis through its discovery of a broader epitope distribution compared to pemphigus vulgaris or pemphigus foliaceous. It is also held that autoantibodies in pemphigus herpetiformis lead to the secretion of proinflammatory cytokines by keratinocytes, especially interleukin-8. This, in turn, consecutively leads to the recruitment and stimulation of inflammatory cells, resulting in eosinophils and/or neutrophils spongiosis and focal intercellular edema that are responsible for the blistering process.[9][10]

Histopathology

Histopathological features of pemphigus herpetiformis differ from pemphigus vulgaris and pemphigus foliaceous because of the presence of spongiosis, mostly without acantholysis. The histological findings may vary among patients, and one patient can have various histological features at different times. Therefore, more than one biopsy may be necessary for the diagnosis of pemphigus herpetiformis. The main histopathological finding of pemphigus herpetiformis is eosinophilic spongiosis. Other reported features include neutrophilic spongiosis, mixed eosinophilic-neutrophilic spongiosis, subcorneal pustules and/or intraepidermal vesicles filled with neutrophils and/or eosinophils. Acantholysis is usually absent but may appear later in the disease process. Dermal papillary neutrophilic microabscesses also can be present. The pattern of immune cell infiltration may vary, being mixed eosinophil neutrophil in 60% of cases, eosinophil dominant in approximately 20%, and neutrophil-dominant in 20%.

History and Physical

Patients affected with pemphigus herpetiformis typically have a subacute onset of disease. The diagnosis of pemphigus herpetiformis is rarely established at the first consultation, as the clinical presentation is usually atypical, and other diseases can be hypothesized such as dermatitis herpetiformis, bullous pemphigoid, and linear IgA bullous dermatosis. Patients affected with pemphigus herpetiformis usually show erythematous, vesicular, bullous, pustular or papular lesions, often in a "herpetiform" pattern and with severe pruritus. Skin lesions tend to present with annular-shaped distribution, probably due to the centrifugal spread of inflammatory processes. In some cases, the main lesions can be urticarial itching papules and plaques. These features are not frequently seen in pemphigus vulgaris and pemphigus foliaceous. The affected sites for pemphigus herpetiformis are mostly the trunk and proximal extremities. Although pemphigus herpetiformis usually manifests a widespread distribution, some cases of atypical and localized lesions have been reported. However, mucous membrane involvement is not a frequent issue. During the clinical course of the disease, pemphigus herpetiformis may evolve into pemphigus vulgaris or pemphigus foliaceous. The opposite has also been reported.

Evaluation

Peripheral blood eosinophilia may be found in some patients. Direct immunofluorescence staining on skin biopsy specimen is similar to the other forms of pemphigus: interkeratinocytic deposits of IgG and C3 most often seen in the superficial layers of the epidermis. Less commonly, these immunoreactants can be seen in the lower layers of the epidermis, mainly when circulating autoantibodies against Dsg3 are present. Indirect immunofluorescence with healthy human skin, the monkey/guinea pig esophagus or rat bladder as a substrate may reveal intercellular binding of IgG antibodies. Enzyme-linked immunosorbent assay and/or immunoblotting can reveal circulating antibodies targeting epidermal proteins, mainly Dsg1, less commonly Dsg3. Recently, other target antigens have been reported such as Dsc1, Dsc3, 178-Kd antigen, BP 180 C-terminus, and laminin 332 gamma2 subunit.

Treatment / Management

Pemphigus herpetiformis usually has an indolent course, and it is less life-threatening than other forms of pemphigus. Some cases, however, may progress into pemphigus vulgaris or pemphigus foliaceous. The small sample sizes limit the evidence base for management of pemphigus herpetiformis. Based on a review of the literature, dapsone and corticosteroids are the drugs mainly prescribed. Pemphigus herpetiformis usually respond well to dapsone which is considered by many authors as the first drug of choice due to its ability to decrease neutrophil migration. Corticosteroids are also frequently reported to be effective in PH, and the daily doses required for complete remission are much lower than those required in pemphigus vulgaris or pemphigus foliaceous. Dapsone and steroids may be given as monotherapy or in combination. More intense therapy modalities have been applied in cases of pemphigus herpetiformis evolving to the classical forms of pemphigus in patients with recalcitrant pemphigus herpetiformis, including cyclophosphamide, mycophenolate mofetil, sulfapyridine, azathioprine, methotrexate, intravenous immunoglobulin, rituximab, and plasmapheresis.[11]

Pearls and Other Issues

Pemphigus herpetiformis is an uncommon subtype of pemphigus with atypical clinical, histological and immunopathological findings. The exact mechanisms underlying pathogenesis remain unclear. The diagnosis of pemphigus herpetiformis is challenging since it is a rare disease with unusual presentation. A significant delay in diagnosis is, therefore, often reported. Intense pruritus associated with urticarial plaques, vesiculobullous eruption in a herpetiform pattern and the absence of mucosal involvement should prompt consideration of the diagnosis. Pemphigus herpetiformis has a good prognosis and responds well to dapsone and/or low doses of steroids; however, some cases may progress into pemphigus vulgaris or pemphigus foliaceous.

Enhancing Healthcare Team Outcomes

Pemphigus herpetiformis is a rare blistering skin disorder that is best managed by a multidisciplinary team including pharmacists. There is no universal treatment for the disorder but many patients do respond to dapsone and corticosteroids. However, many other immunosuppressive agents and biological drugs are now used to treat this disorder with variable success. The patient needs to be educated about the adverse effects of the drugs; which often reduces compliance.


  • Image 6019 Not availableImage 6019 Not available
    Contributed by Talel Badri (2013)
Attributed To: Contributed by Talel Badri (2013)

Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Pemphigus, Herpetiformis - Questions

Take a quiz of the questions on this article.

Take Quiz
A 45-year-old female presents with a 4-month history of a widespread rash and intense itching. Examination reveals a vesiculobullous eruption with annular, crusted, urticated plaques on the trunk and limbs. There is no mucosal involvement. Skin biopsy demonstrates eosinophilic spongiosis with no acantholysis. Direct immunofluorescence reveals epidermal intercellular IgG and C3. What is the most likely diagnosis?

(Move Mouse on Image to Enlarge)
  • Image 6019 Not availableImage 6019 Not available
    Contributed by Talel Badri (2013)
Attributed To: Contributed by Talel Badri (2013)



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
What is the main histological finding in pemphigus herpetiformis?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
What is the most common target autoantigen in pemphigus herpetiformis?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
What is the first line therapy of pemphigus herpetiformis ?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up
What is the main differential diagnosis of pemphigus herpetiformis?



Click Your Answer Below


Would you like to access teaching points and more information on this topic?

Improve Content - Become an Author or Editor and get free access to the entire database, free eBooks, as well as free CME/CE as it becomes available. If interested, please click on "Sign Up" to register.

Purchase- Want immediate access to questions, answers, and teaching points? They can be purchased above at Apps and eBooks.


Sign Up

Pemphigus, Herpetiformis - References

References

Daniel BS,Murrell DF, Review of Autoimmune Blistering Diseases: the Pemphigoid diseases. Journal of the European Academy of Dermatology and Venereology : JEADV. 2019 May 13;     [PubMed]
Shimizu Y,Wakabayashi K,Hayashi Y,Hara K,Aoyama R,Niimi T,Tomino Y,Wada R,Hata M,Suzuki Y, MPGN Type 3 Associated with Pemphigus Herpetiformis Mimicking PGNMID and Dermatitis Herpetiformis. Case reports in nephrology and dialysis. 2019 Jan-Apr;     [PubMed]
Kiritsi D,Schauer F, [Autoimmune blistering dermatoses in children]. Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete. 2019 Apr;     [PubMed]
Witte M,Zillikens D,Schmidt E, Diagnosis of Autoimmune Blistering Diseases. Frontiers in medicine. 2018;     [PubMed]
Costa LMC,Cappel MA,Keeling JH, Clinical, pathologic, and immunologic features of pemphigus herpetiformis: a literature review and proposed diagnostic criteria. International journal of dermatology. 2019 Mar 22;     [PubMed]
Hofmann SC,Juratli HA,Eming R, Bullous autoimmune dermatoses. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. 2018 Nov;     [PubMed]
van Beek N,Zillikens D,Schmidt E, Diagnosis of autoimmune bullous diseases. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG. 2018 Sep;     [PubMed]
Jerbi A,Hachicha H,Feki S,Bahloul E,Sellami K,Abida O,Charfi S,Bouzid A,Sellami Boudawara T,Turki H,Masmoudi A,Masmoudi H, Pemphigus herpetiformis in South Tunisia: a clinical expression of pemphigus foliaceus? International journal of dermatology. 2018 Sep;     [PubMed]
Lakoš Jukić I,Jerković Gulin S,Marinović B, Blistering diseases in the mature patient. Clinics in dermatology. 2018 Mar - Apr;     [PubMed]
Kridin K, Pemphigus group: overview, epidemiology, mortality, and comorbidities. Immunologic research. 2018 Apr;     [PubMed]
Peterman CM,Vadeboncoeur S,Schmidt BA,Gellis SE, Pediatric Pemphigus Herpetiformis: Case Report and Review of the Literature. Pediatric dermatology. 2017 May;     [PubMed]

Disclaimer

The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of Rheumatology. The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for Rheumatology, it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in Rheumatology, you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of Rheumatology. When it is time for the Rheumatology board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study Rheumatology.